BRAINQ drew heightened scientific attention this week as it highlighted new stroke recovery data from its EMAGINE II trial and recognition at the ESOC 2026 conference in Basel. The company was named a “Best Poster” finalist, underscoring growing peer interest in its electromagnetic network targeting field, or ENTF, neuromodulation technology.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Late-breaking EMAGINE II results suggest that extending BRAINQ’s ENTF therapy from three to six months can drive additional functional recovery in post-stroke patients. These findings challenge the traditional view of an early rehabilitation plateau and point to stroke recovery as a more prolonged, continuous process.
The company’s ESOC presence included multiple scientific engagements, such as poster BP14 on extended frequency-tuned neuromodulation and poster P232 on using the delta-to-alpha ratio as a non-invasive spectral biomarker of recovery. A dedicated scientific session on ENTF for stroke recovery, led in part by medical director Dr. Jeff Saver of UCLA, further showcased the platform’s clinical potential.
In parallel, BRAINQ highlighted a peer-reviewed publication from Harvard Boston Children’s Hospital conducted in collaboration with the company. The study supports therapeutic strategies that activate the brain’s natural repair and neuroplasticity mechanisms, reinforcing BRAINQ’s data-driven approach to digital neurorehabilitation.
These academic and conference milestones collectively strengthen BRAINQ’s scientific validation and market positioning in stroke and broader brain health indications. While key details on regulatory timelines, approvals, and commercialization remain undisclosed, the convergence of trial data, peer-reviewed evidence, and high-profile presentations may support future adoption, partnerships, and reimbursement discussions.
Overall, the week marked a constructive period for BRAINQ, with advancing clinical evidence and external recognition bolstering confidence in its long-term, neuroplasticity-focused stroke recovery strategy.